Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06607939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06607939 · ClinicalTrials.gov record · last posted 2026-08-26

ORB-021 In Patients With Advanced Solid Tumors

Study acronym: OR2-01
StatusRecruiting
PhasePhase 1
Started2024-11-21
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.

Protocol amendment history 1 change detected by DataLookout

2026-08-27
Primary completion pushed: 2026-05-29 → 2027-01-29
Trial Details
NCT Number NCT06607939
Lead Sponsor Orionis Biosciences Inc
Conditions Advanced Solid Tumors Cancer
Enrollment 36 participants
Start Date 2024-11-21
Primary Completion 2027-01-29 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-26